Comparison Between Lidocaine Prilocaine Cream and Lidocaine Injection on Pain Control During Episiotomy.

September 3, 2023 updated by: Ahmed ElHarty, Cairo University

Comparison Between the Effects of Lidocaine Prilocaine Cream and Lidocaine Injection on Reduction of Perineal Pain During Episiotomy and Perineum Repair in Vaginal Delivery: Randomized Control Trial

The present study aims to compare the effects of lidocaine-prilocaine cream and lidocaine injection on the reduction of pain while doing and repairing episiotomy, controlling the pain in the post-partum period, and reduction the risk of infection and dyspareunia in 6 weeks post-partum.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Population of study & disease condition:

The study will be conducted on 60 patients that will be admitted to the labor ward in the Department of Obstetrics & Gynecology of a tertiary care center of Cairo University from Jan/2023 to Jan/2024 on. Primigravida women with singleton live pregnancy with cephalic presentation in the first stage of labor will be included in the study after approval by the Institutional Ethical Committee and obtaining an informed consent. Those with known allergy to lignocaine, altered mental status, request for epidural analgesia and hepatic disorders will be excluded from the study. The enrolled women will be divided into two groups by simple randomization with a 1:1 allocation ratio.

The following will be done to all participants:

  • Informed written consent: after discussing the nature of the study as well as the expected value, outcome, and possible adverse effects.
  • Full medical history: including full obstetric history and current pregnancy history (entailing the 1st day of LMP).
  • Thorough Clinical Examination: general (vital signs) and full obstetric examination.
  • Obstetric ultrasonography: to confirm gestational age and the eligibility of the current pregnancy to participate in the study.

This will be a double blinded study, blindness will be achieved by the following: the allocation treatment will be written on cards that will be sealed in sequentially numbered envelopes. The envelopes will be opened at the time of allocation after the enrolled participants will complete all baseline assessments. Group I comprised 30 women who will receive 10 ml of lidocaine 2% for perineal infiltration at the time of crowning while 30 women of Group II will have lidocaine prilocaine cream 15gm application on the perineum at 8 cm of cervical dilatation and then additional dose every 1 hour until delivery is achieved, then another dose of the cream will be applied before repairing the episiotomy and finally daily 3 doses every 8 hours at the site of episiotomy for the first week post-partum. Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.

Fifteen grams of this cream will be applied as a thick layer (about 2 g/ 10 cm2 area) to the intact surface of the perineum and will be covered with an occlusive dressing (Kumar et al., 2015).

In previous study done by Nirmala et al., 2013 The mean pain scores in the study were comparable for both groups, in our study we will increase the dose and the intervals of the applied cream and we will write down the results regarding pain score and side effects.

At the time of crowning, the occlusive dressing and any residue of the cream will be removed and episiotomy will be done. The request for additional anesthetic agent (10 ml of 2% lidocaine solution for both groups) will be honored and recorded for both groups. And if the patient require additional analgesia during episiotomy (VAS more than 3) we will give additional anesthetic agent (10 ml of 2% lidocaine solution. After repair of episiotomy, each patient will be asked to grade the severity of pain during perineal repair on a Visual Analog Scale (VAS). The far left will be labelled 'No pain' and the far right will be labelled as 'worst pain possible'. The subject will be asked to make a vertical mark on this line reflecting the severity of pain.

The patients are followed 6-week post-partum at the OPC or by telephone call to check the pain score by using (Very satisfied - satisfied - not satisfied - dissatisfied).

Post-operative analgesics will include Paracetamol mainly and adjuvant NSAIDs as mentioned in the step ladder pain management by the WHO.

If any further analgesia needed we will use Pethidine as a rescue analgesics as it is safe after delivery but we will prescribe anti emetic with pethidine as it will induce nausea and vomiting.

Pain score during episiotomy repair will be the primary outcome of the study. Secondary outcome measures will include pain score in the first six weeks post-partum, dyspareunia and reduction of the rate of wound infection.

Study location:

Kasr Al Ainy - Causality department (Department 10).

what does research involve? Human participants

Type of consent of study participants:

Written consent

Confidentiality of data:

- All study-related information will be stored at the study site.

Type of the study:

- Randomized Control Trial (RCT)

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Pregnant women candidate for VD ( ASA Ⅱ )
  2. Primigravida
  3. Pregnant more than 37 weeks (Term pregnancy).
  4. Singleton fetus.
  5. Cephalic presentation.
  6. In first stage of labor.

Exclusion Criteria:

  1. More than or equal 1 previous CS and VBAC.
  2. Multiparous women.
  3. Pregnant less than 37 weeks
  4. Twin pregnancy.
  5. Not in active labor
  6. allergy to lignocaine
  7. altered mental status
  8. request for epidural analgesia
  9. Hepatic impairment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group I comprised 30 women who will receive 10 ml of lidocaine 2%
10 ml of lidocaine 2% for perineal infiltration at the time of crowning
Drug: 10 ml of lidocaine 2%
10 ml of lidocaine 2% for perineal infiltration at the time of crowning
Other Names:
  • Local ( injectable ) anesthetic
Active Comparator: Group II will have lidocaine prilocaine cream 15gm application on the perineum
lidocaine-prilocaine cream 15gm application on the perineum at 8 cm of cervical dilatation and then an additional dose every 1 hour until delivery is achieved, then another dose of the cream will be applied before repairing the episiotomy and finally daily 3 doses every 8 hours at the site of episiotomy for the first week post-partum
Drug: lidocaine prilocaine cream 15gm
Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.
Other Names:
  • EMLA cream

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effect of the Intervention on pain score during the repair of episiotomy
Time Frame: 1 year
Efficacy of lidocaine-pridocaine cream in pain control for episiotomy incision and repair assessed by Visual Analogue Score VAS during episiotomy incision and repair where the minimum value is equal to zero which means no pain at all and the maximum value is equal to 10 and this means the worst pain ever.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effect of the Intervention on perineal infection during 6 weeks postpartum
Time Frame: 1 year
Detection of the infection rates 6 weeks post-partum as this is the period of perpurium when puerperal sepsis may develops.
1 year
Effect of the Intervention on pain score and dyspareunia during 6 weeks postpartum
Time Frame: 1 year
Pain score and dyspareunia in the first week post-partum and 6 weeks post-partum will be assessed by Customer Satisfaction Score or CSAT score, where the minimum value is very unsatisfied and associated with the highest degree of pain and the maximum value is very satisfied and this associated with the lowest degree of pain in the period of 1 week and 6 weeks.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Study Director: Ahmed S Alharty, MD, Cairo U

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2023

Primary Completion (Estimated)

September 1, 2024

Study Completion (Estimated)

September 1, 2024

Study Registration Dates

First Submitted

May 26, 2023

First Submitted That Met QC Criteria

June 5, 2023

First Posted (Actual)

June 6, 2023

Study Record Updates

Last Update Posted (Actual)

September 6, 2023

Last Update Submitted That Met QC Criteria

September 3, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MD-12-2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Not for IPD

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Episiotomy Wound

Clinical Trials on 10 ml of lidocaine 2%

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe